Neurocrine Biosciences, Inc.

Good afternoon, everyone, and welcome to today's Neurocrine Biosciences Report's third quarter 2020 results. At this time, all participants are in a listen-only mode. Later, you will have an opportunity to ask questions during the question and answer session. You may register to ask a question at any time by pressing the star and one on your touchtone phone. Please note, this call may be recorded. I will be standing by should you need assistance. It is now my pleasure to turn today's program over to Todd Tushla, Vice President of Investor Relations. Please go ahead.

Great. Thanks, Jamie. Good afternoon, everyone, and thank you for joining our third quarter 2020 earnings call. Joining me on the call is Kevin Gorman, our chief executive officer, Matt Abernethy, our chief financial officer, Irie Roberts, our chief medical officer, Eric Benevich, our chief commercial officer, and Kyle Gano, our chief business development and strategy officer. During today's call, we'll be making forward-looking statements. These statements are subject to certain risks and uncertainties, and our actual results may differ materially. I encourage you to review the risk factors discussed in our latest SEC filings. Following our prepared remarks, we will open the call up for questions and ask that you please limit yourself to one question to give as many people as possible an opportunity to participate. With that, I now turn the call over to Kevin Gorman.

Thanks, Todd. Good afternoon, everyone. Thank you for joining us today. Matt, Eric, Eiry, and I will be keeping our prepared remarks short to allow for the majority of the time for your questions. As you saw from our press release this past quarter, we experienced a fairly significant impact from the pandemic on our business. Psychiatry practices are more heavily influenced by COVID than other specialties. In Q3, approximately 40% of psychiatry offices were not seeing patients in person, and as you know, the majority of our call pattern has been to psychiatrists.